FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207433> ?p ?o ?g. }

• W4387207433 endingPage "e414" @default.
• W4387207433 startingPage "e413" @default.
• W4387207433 abstract "Men with low serum prostate-specific antigen (PSA) and high Gleason grade group (GGG) are thought to have poor outcomes compared to high PSA secretors. However, there is limited outcome data to support this. We report clinical outcomes from a single-institutional cohort of men presenting with locally advanced prostate cancer but low serum PSA.Data from electronic database of a UK tertiary cancer center was acquired for men with histological diagnosis of prostate adenocarcinoma, GGG 4 or 5, stage ≥cT3a, and PSA <10ug/L at diagnosis. Men with metastatic disease, or prior androgen deprivation therapy (ADT) were excluded. Biochemical progression was defined as per Phoenix criteria (PSA > nadir+2) for primary radiotherapy, or PSA >0.2 ug/L after primary prostatectomy (and post-operative radiotherapy, if received). Overall survival (OS, from date of diagnosis to death), metastasis-free survival (MFS, from diagnosis to first recorded metastasis or death), and biochemical progression free survival (bPFS, from diagnosis to biochemical progression or death) were estimated by Kaplan Meier method, and multivariable analysis performed using Cox proportional hazards method.Medical records of 7,200 men presenting with non-metastatic prostate cancer from 2013 to 2021 were screened, of which 270 men satisfying the eligibility criteria were included for this study. Initial analysis of 123 men shows median PSA at presentation 7.1 ug/L (IQR 5.6-8.5), and median age 70 years (IQR 65-75). Histology was GGG 4 in 47.6% and 5 in 52.4%. Tumor stage was cT3a in 56.6%, cT3b in 36.9%, and T4 in 6.6%. Pelvic nodes were involved in 5% patients. Majority (83.7%) were treated with radical radiotherapy (external beam alone 64.2%, brachytherapy boost 19.5%), with 24 months ADT; 11.4% underwent radical prostatectomy, and 4.9% received ADT alone. Three men (2.4%) received docetaxel, and one received abiraterone. At a median follow up of 66 months (IQR 27-77), 36 (29.3%) patients had biochemical failure. Total 23 (18.6%) patients had metastases at recurrence, which were visceral in 4%, bone-only in 10%, and nodal-only in 4%. Total 38 (30.6%) patients had died, 23% with prostate cancer and 11% due to other causes. Five-year bPFS was 65.9%, MFS 69.0%, and OS was 77.4%. GGG 5 (versus 4) was associated with significantly worse 5-year bPFS (59.4% vs 73.9%, HR 1.8, 95% CI 1.0-3.2, p = 0.05) and MFS (59.2% vs 81.6%, HR 2.2, 1.2-4.2, p = 0.02). On multivariable analysis including age and PSA at diagnosis, only GGG 5 was associated with worse bPFS (HR 1.8, 1.0-3.3, p = 0.05) and MFS (HR 2.42, 1.25-4.67, p = 0.009).Men with low secreting but high Gleason grade group prostate cancer are a relatively rare group with poor clinical outcomes despite being non-metastatic. Ongoing work (expected completion June 2023) will analyze remaining cases, and compare outcomes within an expanded multicentric cohort with matched controls having elevated PSA at presentation." @default.
• W4387207433 created "2023-09-30" @default.
• W4387207433 creator A5010055502 @default.
• W4387207433 creator A5019119302 @default.
• W4387207433 creator A5020195132 @default.
• W4387207433 creator A5024785329 @default.
• W4387207433 creator A5032380594 @default.
• W4387207433 creator A5035054500 @default.
• W4387207433 creator A5042448610 @default.
• W4387207433 creator A5044120065 @default.
• W4387207433 creator A5044466390 @default.
• W4387207433 creator A5060916908 @default.
• W4387207433 creator A5061759470 @default.
• W4387207433 creator A5064905917 @default.
• W4387207433 creator A5065195021 @default.
• W4387207433 creator A5082227326 @default.
• W4387207433 creator A5084995927 @default.
• W4387207433 creator A5090442664 @default.
• W4387207433 date "2023-10-01" @default.
• W4387207433 modified "2023-10-17" @default.
• W4387207433 title "Outcomes in Locally Advanced Non-Metastatic Prostate Cancer Presenting with Low PSA at Diagnosis" @default.
• W4387207433 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1561" @default.
• W4387207433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785368" @default.
• W4387207433 hasPublicationYear "2023" @default.
• W4387207433 type Work @default.
• W4387207433 citedByCount "0" @default.
• W4387207433 crossrefType "journal-article" @default.
• W4387207433 hasAuthorship W4387207433A5010055502 @default.
• W4387207433 hasAuthorship W4387207433A5019119302 @default.
• W4387207433 hasAuthorship W4387207433A5020195132 @default.
• W4387207433 hasAuthorship W4387207433A5024785329 @default.
• W4387207433 hasAuthorship W4387207433A5032380594 @default.
• W4387207433 hasAuthorship W4387207433A5035054500 @default.
• W4387207433 hasAuthorship W4387207433A5042448610 @default.
• W4387207433 hasAuthorship W4387207433A5044120065 @default.
• W4387207433 hasAuthorship W4387207433A5044466390 @default.
• W4387207433 hasAuthorship W4387207433A5060916908 @default.
• W4387207433 hasAuthorship W4387207433A5061759470 @default.
• W4387207433 hasAuthorship W4387207433A5064905917 @default.
• W4387207433 hasAuthorship W4387207433A5065195021 @default.
• W4387207433 hasAuthorship W4387207433A5082227326 @default.
• W4387207433 hasAuthorship W4387207433A5084995927 @default.
• W4387207433 hasAuthorship W4387207433A5090442664 @default.
• W4387207433 hasConcept C10515644 @default.
• W4387207433 hasConcept C121608353 @default.
• W4387207433 hasConcept C126322002 @default.
• W4387207433 hasConcept C126894567 @default.
• W4387207433 hasConcept C143998085 @default.
• W4387207433 hasConcept C146357865 @default.
• W4387207433 hasConcept C151730666 @default.
• W4387207433 hasConcept C2776235491 @default.
• W4387207433 hasConcept C2777899217 @default.
• W4387207433 hasConcept C2779013556 @default.
• W4387207433 hasConcept C2779466945 @default.
• W4387207433 hasConcept C2780192828 @default.
• W4387207433 hasConcept C2781406297 @default.
• W4387207433 hasConcept C50382708 @default.
• W4387207433 hasConcept C509974204 @default.
• W4387207433 hasConcept C71924100 @default.
• W4387207433 hasConcept C72563966 @default.
• W4387207433 hasConcept C86803240 @default.
• W4387207433 hasConceptScore W4387207433C10515644 @default.
• W4387207433 hasConceptScore W4387207433C121608353 @default.
• W4387207433 hasConceptScore W4387207433C126322002 @default.
• W4387207433 hasConceptScore W4387207433C126894567 @default.
• W4387207433 hasConceptScore W4387207433C143998085 @default.
• W4387207433 hasConceptScore W4387207433C146357865 @default.
• W4387207433 hasConceptScore W4387207433C151730666 @default.
• W4387207433 hasConceptScore W4387207433C2776235491 @default.
• W4387207433 hasConceptScore W4387207433C2777899217 @default.
• W4387207433 hasConceptScore W4387207433C2779013556 @default.
• W4387207433 hasConceptScore W4387207433C2779466945 @default.
• W4387207433 hasConceptScore W4387207433C2780192828 @default.
• W4387207433 hasConceptScore W4387207433C2781406297 @default.
• W4387207433 hasConceptScore W4387207433C50382708 @default.
• W4387207433 hasConceptScore W4387207433C509974204 @default.
• W4387207433 hasConceptScore W4387207433C71924100 @default.
• W4387207433 hasConceptScore W4387207433C72563966 @default.
• W4387207433 hasConceptScore W4387207433C86803240 @default.
• W4387207433 hasIssue "2" @default.
• W4387207433 hasLocation W43872074331 @default.
• W4387207433 hasLocation W43872074332 @default.
• W4387207433 hasOpenAccess W4387207433 @default.
• W4387207433 hasPrimaryLocation W43872074331 @default.
• W4387207433 hasRelatedWork W1967410728 @default.
• W4387207433 hasRelatedWork W1980188241 @default.
• W4387207433 hasRelatedWork W2118670275 @default.
• W4387207433 hasRelatedWork W2402249956 @default.
• W4387207433 hasRelatedWork W2545489389 @default.
• W4387207433 hasRelatedWork W2897445903 @default.
• W4387207433 hasRelatedWork W2904168711 @default.
• W4387207433 hasRelatedWork W4241710403 @default.
• W4387207433 hasRelatedWork W4319748405 @default.
• W4387207433 hasRelatedWork W193188344 @default.
• W4387207433 hasVolume "117" @default.
• W4387207433 isParatext "false" @default.
• W4387207433 isRetracted "false" @default.
• W4387207433 workType "article" @default.